INCA33890

Phase 3Small molecule

Incyte

INCA33890 is one of 36 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

CRC (colorectal Cancer)Recruiting

Colorectal CancerPhase 3

Active, not recruiting

CRC (colorectal Cancer)Phase 3

Recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

INCA33890

Incyte

Phase 3

3 2

Eylea

Regeneron

Preclinical

5 3

Ketalar

AAultman Health Foundation

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Vascepa

AAmarin Pharma Inc.

Preclinical

1 9

Andriol

AAuxilium

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Advanced or Metastatic Solid Tumors

NCT06179160

Phase 1Recruiting

Advanced or Metastatic Solid Tumors

NCT05836324

Q3 2029

Phase 3Recruiting

CRC (colorectal Cancer)

NCT07284849

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors2 trials

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting· Incyte logo

Incyte·Phase 1·NCT06179160·710 enrolled

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting· Incyte logo

Incyte·Phase 1·NCT05836324·408 enrolled

CRC (Colorectal Cancer)1 trial

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Recruiting· Incyte logo

Incyte·Phase 3·NCT07284849·700 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for INCA33890. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCA33890 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCA33890. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Incyte

INCA33890

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2029

Trials by Indication[1]

Advanced or Metastatic Solid Tumors2 trials

CRC (Colorectal Cancer)1 trial

References

Drug Info

Quick Facts

Related News